Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

The role of scientific evidence in decisions to adopt complex innovations in cancer care settings: a multiple case study in Nova Scotia, Canada.

Urquhart R, Kendell C, Geldenhuys L, Ross A, Rajaraman M, Folkes A, Madden LL, Sullivan V, Rayson D, Porter GA.

Implement Sci. 2019 Feb 12;14(1):14. doi: 10.1186/s13012-019-0859-5.

2.

Making It Happen: Middle Managers' Roles in Innovation Implementation in Health Care.

Urquhart R, Kendell C, Folkes A, Reiman T, Grunfeld E, Porter GA.

Worldviews Evid Based Nurs. 2018 Dec;15(6):414-423. doi: 10.1111/wvn.12324. Epub 2018 Oct 6.

3.

Factors influencing middle managers' commitment to the implementation of innovations in cancer care.

Urquhart R, Kendell C, Folkes A, Reiman T, Grunfeld E, Porter G.

J Health Serv Res Policy. 2019 Apr;24(2):91-99. doi: 10.1177/1355819618804842. Epub 2018 Oct 5.

PMID:
30290703
4.

The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.

Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz-Romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Child F, Whittaker S, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram-Wolff C, Battistella M, Alberti-Violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot-Barry M, Pham-Ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel-Kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon-Pennamen MD, Battistella M, Climent F, Gonzalez-Barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots AM, Hauben E, Bervoets A, Woei-A-Jin FJSH, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, McKay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches JA, Miyashiro D, Akilov O, McCann S, Sahi H, Damasco FM, Querfeld C, Folkes A, Bur C, Klemke CD, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R.

Br J Dermatol. 2019 Aug;181(2):350-357. doi: 10.1111/bjd.17258. Epub 2018 Nov 25.

PMID:
30267549
5.

Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience.

Folkes AS, Feng M, Zain JM, Abdulla F, Rosen ST, Querfeld C.

Curr Opin Oncol. 2018 Sep;30(5):332-337. doi: 10.1097/CCO.0000000000000468. Review.

6.

Views of breast and colorectal cancer survivors on their routine follow-up care.

Urquhart R, Folkes A, Babineau J, Grunfeld E.

Curr Oncol. 2012 Dec;19(6):294-301. doi: 10.3747/co.19.1051.

7.

Population-based longitudinal study of follow-up care for patients with colorectal cancer in Nova Scotia.

Urquhart R, Folkes A, Porter G, Kendell C, Cox M, Dewar R, Grunfeld E.

J Oncol Pract. 2012 Jul;8(4):246-52. doi: 10.1200/JOP.2011.000491.

8.

Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer.

Grunfeld E, Julian JA, Pond G, Maunsell E, Coyle D, Folkes A, Joy AA, Provencher L, Rayson D, Rheaume DE, Porter GA, Paszat LF, Pritchard KI, Robidoux A, Smith S, Sussman J, Dent S, Sisler J, Wiernikowski J, Levine MN.

J Clin Oncol. 2011 Dec 20;29(36):4755-62. doi: 10.1200/JCO.2011.36.8373. Epub 2011 Oct 31.

PMID:
22042959
9.

Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.

Heffron TP, Wei B, Olivero A, Staben ST, Tsui V, Do S, Dotson J, Folkes AJ, Goldsmith P, Goldsmith R, Gunzner J, Lesnick J, Lewis C, Mathieu S, Nonomiya J, Shuttleworth S, Sutherlin DP, Wan NC, Wang S, Wiesmann C, Zhu BY.

J Med Chem. 2011 Nov 24;54(22):7815-33. doi: 10.1021/jm2007084. Epub 2011 Oct 21.

PMID:
21985639
10.

Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.

Staben ST, Heffron TP, Sutherlin DP, Bhat SR, Castanedo GM, Chuckowree IS, Dotson J, Folkes AJ, Friedman LS, Lee L, Lesnick J, Lewis C, Murray JM, Nonomiya J, Olivero AG, Plise E, Pang J, Prior WW, Salphati L, Rouge L, Sampath D, Tsui V, Wan NC, Wang S, Weismann C, Wu P, Zhu BY.

Bioorg Med Chem Lett. 2010 Oct 15;20(20):6048-51. doi: 10.1016/j.bmcl.2010.08.067. Epub 2010 Aug 19.

PMID:
20822905
11.

Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.

Heffron TP, Berry M, Castanedo G, Chang C, Chuckowree I, Dotson J, Folkes A, Gunzner J, Lesnick JD, Lewis C, Mathieu S, Nonomiya J, Olivero A, Pang J, Peterson D, Salphati L, Sampath D, Sideris S, Sutherlin DP, Tsui V, Wan NC, Wang S, Wong S, Zhu BY.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2408-11. doi: 10.1016/j.bmcl.2010.03.046. Epub 2010 Mar 12.

PMID:
20346656
12.

Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.

Sutherlin DP, Sampath D, Berry M, Castanedo G, Chang Z, Chuckowree I, Dotson J, Folkes A, Friedman L, Goldsmith R, Heffron T, Lee L, Lesnick J, Lewis C, Mathieu S, Nonomiya J, Olivero A, Pang J, Prior WW, Salphati L, Sideris S, Tian Q, Tsui V, Wan NC, Wang S, Wiesmann C, Wong S, Zhu BY.

J Med Chem. 2010 Feb 11;53(3):1086-97. doi: 10.1021/jm901284w.

PMID:
20050669
13.

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.

Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, De Haven Brandon A, Di Stefano F, Hayes A, Henley AT, Lensun L, Pergl-Wilson G, Robson A, Saghir N, Zhyvoloup A, McDonald E, Sheldrake P, Shuttleworth S, Valenti M, Wan NC, Clarke PA, Workman P.

Mol Cancer Ther. 2009 Jul;8(7):1725-38. doi: 10.1158/1535-7163.MCT-08-1200. Epub 2009 Jul 7.

14.

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ.

J Med Chem. 2008 Sep 25;51(18):5522-32. doi: 10.1021/jm800295d.

PMID:
18754654
15.

Are leading medical journals following their own policies on CONSORT reporting?

Folkes A, Urquhart R, Grunfeld E.

Contemp Clin Trials. 2008 Nov;29(6):843-6. doi: 10.1016/j.cct.2008.07.004. Epub 2008 Jul 24.

PMID:
18703165
16.

Do available questionnaires measure the communication factors that patients and families consider important at end of life?

Grunfeld E, Folkes A, Urquhart R.

J Clin Oncol. 2008 Aug 10;26(23):3874-8. doi: 10.1200/JCO.2007.15.8006. Review.

PMID:
18688055
17.

Toward population-based indicators of quality end-of-life care: testing stakeholder agreement.

Grunfeld E, Urquhart R, Mykhalovskiy E, Folkes A, Johnston G, Burge FI, Earle CC, Dent S.

Cancer. 2008 May 15;112(10):2301-8. doi: 10.1002/cncr.23428.

18.

Breast Cancer Guidelines in Canada: A Review of Development and Implementation.

Folkes A, Urquhart R, Zitzelsberger L, Grunfeld E.

Breast Care (Basel). 2008;3(2):108-113. Epub 2008 Apr 22.

19.

Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.

Wang S, Wan NC, Harrison J, Miller W, Chuckowree I, Sohal S, Hancox TC, Baker S, Folkes A, Wilson F, Thompson D, Cocks S, Farmer H, Boyce A, Freathy C, Broadbridge J, Scott J, Depledge P, Faint R, Mistry P, Charlton P.

J Med Chem. 2004 Mar 11;47(6):1339-50.

PMID:
14998324
20.

Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.

Wang S, Folkes A, Chuckowree I, Cockcroft X, Sohal S, Miller W, Milton J, Wren SP, Vicker N, Depledge P, Scott J, Smith L, Jones H, Mistry P, Faint R, Thompson D, Cocks S.

J Med Chem. 2004 Mar 11;47(6):1329-38.

PMID:
14998323
21.

ONT-093 (Ontogen).

Mistry P, Folkes A.

Curr Opin Investig Drugs. 2002 Nov;3(11):1666-71. Review.

PMID:
12476971
22.

Novel inhibitors of plasminogen activator inhibitor-1: development of new templates from diketopiperazines.

Wang S, Golec J, Miller W, Milutinovic S, Folkes A, Williams S, Brooks T, Hardman K, Charlton P, Wren S, Spencer J.

Bioorg Med Chem Lett. 2002 Sep 2;12(17):2367-70.

PMID:
12161135
23.

Design, synthesis and in vitro evaluation of potent, novel, small molecule inhibitors of plasminogen activator inhibitor-1.

Folkes A, Brown SD, Canne LE, Chan J, Engelhardt E, Epshteyn S, Faint R, Golec J, Hanel A, Kearney P, Leahy JW, Mac M, Matthews D, Prisbylla MP, Sanderson J, Simon RJ, Tesfai Z, Vicker N, Wang S, Webb RR, Charlton P.

Bioorg Med Chem Lett. 2002 Apr 8;12(7):1063-6.

PMID:
11909718
24.

Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents.

Vicker N, Burgess L, Chuckowree IS, Dodd R, Folkes AJ, Hardick DJ, Hancox TC, Miller W, Milton J, Sohal S, Wang S, Wren SP, Charlton PA, Dangerfield W, Liddle C, Mistry P, Stewart AJ, Denny WA.

J Med Chem. 2002 Jan 31;45(3):721-39.

PMID:
11806724
25.

Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1.

Folkes A, Roe MB, Sohal S, Golec J, Faint R, Brooks T, Charlton P.

Bioorg Med Chem Lett. 2001 Oct 8;11(19):2589-92.

PMID:
11551756
26.

The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.

Nutting C, Folkes A.

Clin Oncol (R Coll Radiol). 1999;11(1):66. No abstract available.

PMID:
10194593
27.

Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives.

Roe M, Folkes A, Ashworth P, Brumwell J, Chima L, Hunjan S, Pretswell I, Dangerfield W, Ryder H, Charlton P.

Bioorg Med Chem Lett. 1999 Feb 22;9(4):595-600.

PMID:
10098671
28.

Once weekly irradiation for carcinoma of the bladder.

Rostom AY, Tahir S, Gershuny AR, Kandil A, Folkes A, White WF.

Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):289-92.

PMID:
8635935
29.

A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma.

Lawton PA, Spittle MF, Ostrowski MJ, Young T, Madden F, Folkes A, Hill BT, MacRae K.

Clin Oncol (R Coll Radiol). 1993;5(2):80-4.

PMID:
8481365
30.

Radiotherapy for Paget's disease of the nipple: a conservative alternative.

Stockdale AD, Brierley JD, White WF, Folkes A, Rostom AY.

Lancet. 1989 Sep 16;2(8664):664-6.

PMID:
2570909
31.

Systemic irradiation in multiple myeloma: a report on nineteen cases.

Rostom AY, O'Cathail SM, Folkes A.

Br J Haematol. 1984 Nov;58(3):423-31.

PMID:
6208931
32.

Aminoglutethimide therapy for advanced carcinoma of the prostate.

Rostom AY, Folkes A, Lord C, Notley RG, Schweitzer FA, White WF.

Br J Urol. 1982 Oct;54(5):552-5.

PMID:
7171963

Supplemental Content

Loading ...
Support Center